These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 27537991)

  • 21. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab for the treatment of atopic dermatitis: A clinical trial review.
    McGregor S; Farhangian ME; Feldman SR
    Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26428945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines.
    Renert-Yuval Y; Guttman-Yassky E
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):28-35. PubMed ID: 31622669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of Systemic Treatment Options for Adult Atopic Dermatitis.
    Gooderham M; Lynde CW; Papp K; Bourcier M; Guenther L; Gulliver W; Hong CH; Poulin Y; Sussman G; Vender R
    J Cutan Med Surg; 2017; 21(1):31-39. PubMed ID: 27635033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the Association Between Atopic Dermatitis and Malignancy: A Comprehensive Review with Therapeutic Strategies.
    Drum DL; Wan LS; Jallorina AG; Lee-Wong MF
    Dermatol Clin; 2024 Oct; 42(4):625-634. PubMed ID: 39278716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.
    Dubin C; Del Duca E; Guttman-Yassky E
    Expert Rev Clin Immunol; 2021 Aug; 17(8):835-852. PubMed ID: 34106037
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel topical and systemic therapies in atopic dermatitis.
    Suga H; Sato S
    Immunol Med; 2019 Jun; 42(2):84-93. PubMed ID: 31318324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options.
    Lopes A; Sokolova A; Abreu C; Lopes C
    Eur Ann Allergy Clin Immunol; 2020 Jan; 52(1):4-14. PubMed ID: 31789489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel therapies in the treatment of atopic dermatitis.
    Zhong CS; Elmariah SB
    Semin Cutan Med Surg; 2018 Sep; 37(3):190-197. PubMed ID: 30215637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapies for atopic dermatitis: Additional treatment classes.
    Vakharia PP; Silverberg JI
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S76-S83. PubMed ID: 29248520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab: Mechanism of action, clinical, and translational science.
    McCann MR; Kosloski MP; Xu C; Davis JD; Kamal MA
    Clin Transl Sci; 2024 Aug; 17(8):e13899. PubMed ID: 39080841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
    Wollenberg A; Howell MD; Guttman-Yassky E; Silverberg JI; Kell C; Ranade K; Moate R; van der Merwe R
    J Allergy Clin Immunol; 2019 Jan; 143(1):135-141. PubMed ID: 29906525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis.
    Hamann CR; Thyssen JP
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S37-S42. PubMed ID: 29248521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tralokinumab for the Treatment of Atopic Dermatitis.
    Freitas E; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2021 Sep; 22(5):625-638. PubMed ID: 34155602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018.
    Werfel T
    Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):432-437. PubMed ID: 30095475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis.
    Kim ST; Lee KM; Park HJ; Jin SE; Ahn WS; Kim CK
    J Gene Med; 2009 Jan; 11(1):26-37. PubMed ID: 19006098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.